Five top-selling drugs, in some cases, are costing Americans thousands in out of pocket expenses weekly and monthly. Here's the list.

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence in the company's largest market.

The U.S. drugmaker is turning to deals at a time when two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.

Karuna’s crown jewel, an experimental drug called KarXT, is the product of such new insights. The drug could surpass $6 billion in yearly sales if it is approved for the various uses.

More than 40 groups have signed onto a letter asking Congress to end the prescription drug price control scheme included in the Inflation Reduction Act.

Western health care companies continue supplying medicine, vaccines and medical equipment to Russia.

Drugmakers raised prices an average of 6.6% at the start of 2022.

President Biden is set to lay out his vision Thursday for reducing the high cost of prescription drugs, and is expected to push Congress to pass legislation that would allow Medicare to negotiate drug prices for millions of Americans.

U.S. equity futures were pointing lower ahead of Wednesday's opening bell on Wall Street.

Warren Buffett's Berkshire Hathaway cut back on financial, energy and drug stocks but beefed up its grocery and wireless holdings while adding an insurer.